Bristol-Myers Squibb Company (BMY)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -8,394,000 | 8,425,000 | 7,695,000 | 8,078,000 | -6,891,000 |
| Revenue | US$ in thousands | 48,300,000 | 45,006,000 | 46,159,000 | 46,385,000 | 42,518,000 |
| Pretax margin | -17.38% | 18.72% | 16.67% | 17.42% | -16.21% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $-8,394,000K ÷ $48,300,000K
= -17.38%
The pretax margin of Bristol-Myers Squibb Company has exhibited fluctuating trends over the years, based on the data provided.
As of December 31, 2020, the company reported a negative pretax margin of -16.21%, indicating that expenses exceeded its gross revenue before accounting for taxes. However, there was a significant improvement in performance by December 31, 2021, with the pretax margin increasing to 17.42%, reflecting better cost management and potentially higher revenue generation.
In the following years, Bristol-Myers Squibb maintained relatively strong pretax margins, with values of 16.67% as of December 31, 2022, and 18.72% as of December 31, 2023. These consistent margins suggest efficient operations and solid financial health.
However, by December 31, 2024, the pretax margin dipped back into negative territory at -17.38%, potentially indicating challenges or increased expenses impacting profitability in that period.
Overall, Bristol-Myers Squibb's pretax margin has shown a mix of positive and negative performance, highlighting the importance of closely monitoring cost structures and revenue streams to sustain profitability in the dynamic pharmaceutical industry.
Peer comparison
Dec 31, 2024